Click here for flash
Register for Updates
Be notified when new content and features are added to CLLPerspectives.com. Go
CLL Perspectives features the latest news and clinical information about CLL, brought to you in part by our advisory board of leading CLL experts. Access up-to-date clinical reviews, download educational resources and hear from our advisors on key topics in CLL. Our goal is to help you achieve better outcomes for your CLL patients. Learn more about us.
Featured Perspectives

Farrukh Awan, MD, MS
John C. Byrd, MD

Staging and Prognostic Factors in CLL
Thus far, no study has shown a survival advantage with early treatment in patients with CLL and a subset of CLL patients will never require therapy. This has led to the research efforts in CLL that have identified several specific biologic or clinical prognostic factors that predict time to progression and overall survival. With these recent...

Constantine S. Tam, MB, BS Susan Lerner, MS
Michael J. Keating, MB, BS

New Prognostic Markers in CLL
The recent proliferation of new "prognostic markers" in chronic lymphocytic leukemia (CLL) has provided valuable insights into the biology of the disease.1 In particular, significant survival differences when patients are classified by immunoglobulin heavy chain variable region (IGVH) mutation status2,3, fluorescent in-situ hybridization (FISH)...
Read more Read more

News & Commentary - provided by Medworm

 

Researchers tackle cll, diabetes and trauma-hemorrhage - molecular medicine, a bi-monthly journal

Chronic Lymphocytic Leukemia (CLL) is a disease of the B lymphocytes of the immune system. Under normal conditions, B lymphocytes (or B cells) play an important role in battling infection. CLL is a disease manifested by uncontrolled growth of these B lymphocytes. In this month's issue of (Source: Lymphoma / Leukemia News From Medical News Today)

Source: Lymphoma / Leukemia News From Medical News Today - Tuesday, November 18, 2008

Cv technologies inc.: world's top cancer research body sponsors landmark cold-fx(r) trial

EDMONTON, ALBERTA (MARKET WIRE) CV Technologies Inc. (TSX: CVQ) today announced that COLD-FX(R) will be the focus of a landmark U.S. National Cancer Institute (NCI) sponsored trial involving chronic lymphocytic leukemia patients - the first time the natural medicine will be part of a clinical study associated with cancer. The NCI, part of the U.S. National Institutes of Health, is the world's most prestigious cancer research body. The trial will be conducted by American cancer and infectious diseases experts at Wake Forest University School of Medicine in Winston-Salem, North Carolina. (Source: Market Wire - Pharmaceuticals and Biotech)

Source: Market Wire - Pharmaceuticals and Biotech - Monday, November 17, 2008